Clinical Neurologic Features and Evaluation of PTEN Hamartoma Tumor Syndrome: A Systematic Review.

Autor:	Dhawan A; From the Genomic Medicine Institute, Lerner Research Institute, Cleveland Clinic, OH., Baitamouni S; From the Genomic Medicine Institute, Lerner Research Institute, Cleveland Clinic, OH., Liu D; From the Genomic Medicine Institute, Lerner Research Institute, Cleveland Clinic, OH., Eng C; From the Genomic Medicine Institute, Lerner Research Institute, Cleveland Clinic, OH.
Jazyk:	angličtina
Zdroj:	Neurology [Neurology] 2024 Oct 08; Vol. 103 (7), pp. e209844. Date of Electronic Publication: 2024 Sep 09.
DOI:	10.1212/WNL.0000000000209844
Abstrakt:	Background and Objectives: PTEN hamartoma tumor syndrome (PHTS) is a well-recognized hereditary tumor syndrome and is now also recognized as a common cause of monogenic autism spectrum disorder. There is a vast spectrum of phenotypic variability across individuals with PHTS, and in addition to neurodevelopmental challenges, patients with PHTS may experience a wide variety of neurologic challenges, many of which have only recently been described. Thus, this systematic review aimed to summarize the breadth of the current knowledge of neurologic conditions in individuals with PHTS. Methods: We conducted a systematic review using the MEDLINE and EMBASE databases until January 2023. We included studies that reported neurologic signs, symptoms, and diagnoses in patients with a diagnosis of PHTS. Two independent reviewers extracted data (neurologic diagnoses and patient details) from each study. Case reports, case series, prospective studies, and therapeutic trials were included. We assessed the quality of evidence using the appropriate tool from the JBI, depending on study design. Results: One thousand nine hundred ninety-six articles were screened, and 90 articles met the inclusion criteria. The majority of the included studies were case reports (49/90, 54%) or small case series (31/90, 34%). Epilepsy secondary to cerebral malformations, neurologic deficits from spinal or cranial arteriovenous malformations, and rare tumors such as dysplastic cerebellar gangliocytoma are among the more severe neurologic features reported across patients with PHTS. One interventional randomized control trial examining neurocognitive endpoints was identified and did not meet its efficacy endpoint. Discussion: Our systematic review defines a broad scope of neurologic comorbidities occurring in individuals with PHTS. Neurologic findings can be categorized by age at onset in individuals with PTHS. Our study highlights the need for additional clinical trial endpoints, informed by the neurologic challenges faced by individuals with PHTS.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu